CSPC Innovation Pharmaceutical (300765.SZ) subsidiary SYS6023 antibody-drug conjugate obtains approval for clinical trials.

CSPC Innovation Pharmaceutical (300765.SZ) announced that its subsidiary, CSPC PHARMA Giant Stone Biopharmaceutical Co., Ltd. ("Giant Stone Biopharma"), recently received approval from the National Medical Products Administration to conduct clinical trials for SYS6023. The clinical trials will commence soon. SYS6023 is a HER3-targeting antibody-drug conjugate that uses the company's Topoisomerase I inhibitor as the payload. It can bind to specific receptors on the surface of tumor cells, enter the cells through endocytosis, release toxins, and effectively kill tumor cells. The payload of SYS6023 is not a substrate for efflux pumps, which is expected to avoid resistance caused by efflux seen in other ADCs of the DXd class.